Helios - For the fiscal year ending December 2024, significant revenue growth is expected, and research and development will be promoted in the fields of somatic stem cell regenerative Pharmaceuticals and iPSC regenerative Pharmaceuticals.

Helios <4593> announced its consolidated financial results (IFRS) for the fiscal year ending December 2024 on the 14th.

Fisco JapanFeb 17 01:09 ET

Sasemod --- Although revenue decreased in the second quarter, an upward revision of the financial estimates for the full year has been announced.

Sasmendo <4263> announced on the 14th its financial results for the second quarter of the fiscal year ending June 2025 (July to December 2024). Business revenue decreased by 72.2% compared to the same period last year, totaling 0.073 billion yen, with an operating loss of 0.308 billion yen (compared to a loss of 0.097 billion yen for the same period last year), an ordinary loss of 0.309 billion yen (compared to a loss of 0.09 billion yen), and a net interim loss of 0.313 billion yen (compared to a loss of 0.091 billion yen). There was no recorded business revenue from the DTx product business (which had 0.2 billion yen in business revenue in the same period last year), and the segment loss is

Fisco JapanFeb 16 22:47 ET

Anges - Significant increase in revenue for the fiscal year ending December 2024, driven by the sales of the progeria treatment drug 'Zokinvi' and an increase in expanded neonatal screening contracts.

On the 14th, AnGes <4563> announced its consolidated financial results for the fiscal year ending December 2024. Revenue was 0.643 billion yen, up 320.7% compared to the previous period, with an operating loss of 9.109 billion yen (previous period was a loss of 11.967 billion yen), a recurring loss of 7.537 billion yen (previously a loss of 5.651 billion yen), and a net loss attributable to shareholders of the parent company of 28.128 billion yen (previously a loss of 7.437 billion yen). The business revenue for the year saw a significant increase compared to the previous period. The company group will start early aging on May 27, 2024.

Fisco JapanFeb 16 22:46 ET

Alfressa HD, MonotaRO, etc. (additional) Rating

Downgrade - Bearish Code Stock Name Securities Company Previous Change After ------------------------------------------------------------ <3659> Nexon Macquarie "Outperform" "Neutral" <6273> SMC Macquarie "Outperform" "Neutral" <6841> Yokogawa Electric Daiwa "2" "3" Target Price Change Code Stock Name Securities Company Previous Change After --------------------

Fisco JapanFeb 16 21:30 ET

Strong performance, supported by the rise in nasdaq and the decline in U.S. long-term gold rates.

[Emerging Markets Individual Stock Global Strategy] Today's emerging markets are expected to exhibit a firm trend. Last Friday, on the 14th, the US stock market saw the Dow Inc drop by 165.35 points (-0.37%) to 44,546.08, reversing its gains. Concerns about an economic downturn arose due to a greater-than-expected drop in January retail revenue, along with profit-taking ahead of the consecutive holidays putting pressure on stock prices. On the other hand, buying driven by expectations of a rate cut strengthened in the Nasdaq, while the rise of NVIDIA and Meta led to a firm performance throughout the day.

Fisco JapanFeb 16 18:20 ET

Investor sentiment is good, trading volume is increasing, and the Growth 250 is becoming aware of breaking through last July's high.

The Emerging Markets this week may reach the significant 700 point level, with trading continuing to focus on Earnings Reports as material. The trading volume at the end of last week swelled to 200 billion yen for the first time this year, indicating strong investment enthusiasm among investors. The Growth Market 250 Index saw a rise to levels not seen since 697.56 points on July 18, 2024. As the weekend approached, Sell-offs were predominant; however, since there was a halt in declines at the high level seen on January 30, the trend of testing for a rebound is intact.

Fisco JapanFeb 16 18:00 ET